Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pha

DelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Acne Vulgaris, historical and forecasted epidemiology as well as the Acne Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acne Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acne Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acne Vulgaris Market Report:
• The Acne Vulgaris market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2023, Ascletis Pharma initiated a Phase III clinical trial for ASC40 (Denifanstat), its drug candidate designed to address moderate to severe acne vulgaris in China. This trial, which is multicenter, double-blind, randomized, and placebo-controlled, aims to evaluate the effectiveness and safety of ASC40.
• In December 2023, Dermata Therapeutics initiated enrollment of the initial participant in the Phase III STAR-1 clinical trial for its topical product candidate, DMT310, aimed at managing moderate-to-severe acne. STAR-1 represents the primary of two Phase III investigations in the DMT310 Phase III clinical program, focusing on evaluating the safety, effectiveness, and tolerability of the product among individuals with facial acne.
• BPX-01, DP-120, GT20029, and other promising treatments are showing encouraging top-line outcomes in their clinical trials. These emerging therapies are currently in the middle phase of clinical development and are poised for launch, which will significantly strengthen the pipeline.
• In 2023, there were approximately 140.2 million prevalent cases of Acne Vulgaris across the 7MM, with around 69.5 million cases in the US alone. These figures are projected to rise steadily during the forecast period.
• Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
• Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
• The Acne Vulgaris epidemiology based on gender analyzed that females are predominantly affected compared to males
• The Acne Vulgaris market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acne Vulgaris pipeline products will significantly revolutionize the Acne Vulgaris market dynamics.

Acne Vulgaris Overview
Acne vulgaris, commonly known as acne, is a chronic skin condition characterized by the formation of pimples, blackheads, whiteheads, cysts, and nodules. It typically occurs when hair follicles become clogged with oil and dead skin cells, leading to the growth of bacteria known as Propionibacterium acnes. Acne commonly appears on the face, neck, chest, back, and shoulders.

Get a Free sample for the Acne Vulgaris Market Report:
https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acne Vulgaris Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Acne Vulgaris Epidemiology Segmentation:
The Acne Vulgaris market report proffers epidemiological analysis for the study period 2024-2034 in the 7MM segmented into:
• Total Prevalence of Acne Vulgaris
• Prevalent Cases of Acne Vulgaris by severity
• Gender-specific Prevalence of Acne Vulgaris
• Diagnosed Cases of Episodic and Chronic Acne Vulgaris
Download the report to understand which factors are driving Acne Vulgaris epidemiology trends @ Acne Vulgaris Epidemiology Forecast
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acne Vulgaris Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acne Vulgaris market or expected to get launched during the study period. The analysis covers Acne Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acne Vulgaris Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Acne Vulgaris Therapies and Key Companies
• BPX-01: BioPharmX
• IDP-120: Bausch Health Americas, Inc.
• GT20029: Kintor Pharma
• KX-826: KintorPharma
• S6G5T-3: Sol-Gel Technologies, Ltd.
• ASC40: Ascletis Pharma
• GK530G: Galderma R&D
• Dapsone: Torrent Pharma
• DMT310: Dermata Therapeutics
• CD5789 (trifarotene): Galderma R&D
• Afamelanotide: Clinuvel Pharma
• NVN1000: Novan, Inc.
• Hydrogen Peroxide: Dermata Therapeutics
• Trifarotene Cream: Galderma R&D
• S6G5T-3: Accelovance
• GDC 268 Lotion: Balmoral Medical
• Isotretinoin: Vyne Therapeutics Inc.
• gevokizumab: XOMA (US) LLC
• BLI1100: Braintree Laboratories
• AKLIEF®: Teva Pharma
• Imsidolimab: AnaptysBio, Inc.
• RA-18C3: Janssen Research
• FMX101: Cutia Therapeutics
• IDP-126: Bausch Health
Discover more about therapies set to grab major Acne Vulgaris market share @ Acne Vulgaris Treatment Market
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Acne Vulgaris Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
• Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
• Acne Vulgaris Therapeutic Assessment: Acne Vulgaris current marketed and Acne Vulgaris emerging therapies
• Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acne Vulgaris Unmet Needs, KOL's views, Analyst's views, Acne Vulgaris Market Access and Reimbursement

To know more about Acne Vulgaris companies working in the treatment market, visit @ Acne Vulgaris Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acne Vulgaris Market Report Introduction
2. Executive Summary for Acne Vulgaris
3. SWOT analysis of Acne Vulgaris
4. Acne Vulgaris Patient Share (%) Overview at a Glance
5. Acne Vulgaris Market Overview at a Glance
6. Acne Vulgaris Disease Background and Overview
7. Acne Vulgaris Epidemiology and Patient Population
8. Country-Specific Patient Population of Acne Vulgaris
9. Acne Vulgaris Current Treatment and Medical Practices
10. Acne Vulgaris Unmet Needs
11. Acne Vulgaris Emerging Therapies
12. Acne Vulgaris Market Outlook
13. Country-Wise Acne Vulgaris Market Analysis (2020-2034)
14. Acne Vulgaris Market Access and Reimbursement of Therapies
15. Acne Vulgaris Market Drivers
16. Acne Vulgaris Market Barriers
17. Acne Vulgaris Appendix
18. Acne Vulgaris Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Acne Vulgaris Pipeline https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Acne Vulgaris Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acne Vulgaris market. A detailed picture of the Acne Vulgaris pipeline landscape is provided, which includes the disease overview and Acne Vulgaris treatment guidelines.

Acne Vulgaris Epidemiology https://www.delveinsight.com/report-store/acne-vulgaris-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acne Vulgaris Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market
DelveInsight's "Retinoblastoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Retinoblastoma, historical and forecasted epidemiology as well as the Retinoblastoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom).

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
DelveInsight's "Thymus Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Thymus Cancer, historical and forecasted epidemiology as well as the Thymus Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.